美康生物
(300439)
| 流通市值：29.73亿 | | | 总市值：39.12亿 |
| 流通股本：2.92亿 | | | 总股本：3.84亿 |
| 报告期 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 481,512,053.72 | 1,885,869,216.24 | 1,470,634,733 | 976,807,779.93 |
| 营业收入 | 481,512,053.72 | 1,885,869,216.24 | 1,470,634,733 | 976,807,779.93 |
| 二、营业总成本 | 412,341,013.66 | 1,661,436,545.22 | 1,270,149,197.62 | 834,293,120.48 |
| 营业成本 | 278,005,340.56 | 1,044,688,488.54 | 810,573,354.36 | 542,445,348.89 |
| 税金及附加 | 3,984,164.36 | 19,152,132.4 | 15,888,736.12 | 8,051,872.85 |
| 销售费用 | 54,713,228.15 | 262,518,784.98 | 196,052,347.63 | 120,542,250.3 |
| 管理费用 | 39,870,866.41 | 186,994,968.06 | 132,840,744.31 | 87,241,892.23 |
| 研发费用 | 38,296,282.28 | 149,801,308.32 | 118,629,648.8 | 78,000,748.72 |
| 财务费用 | -2,528,868.1 | -1,719,137.08 | -3,835,633.6 | -1,988,992.51 |
| 其中:利息费用 | 338,362.53 | 10,663,476.73 | 4,243,536.76 | 3,619,087.41 |
| 其中:利息收入 | 2,992,695.87 | 13,270,425.14 | 8,175,111.67 | 5,783,436.64 |
| 加:公允价值变动收益 | 201,200 | - | - | - |
| 加:投资收益 | 1,680,076.74 | 14,927,419.15 | 10,456,317.68 | 4,612,998.22 |
| 资产处置收益 | 16,897.5 | -782,381.79 | -71,681.15 | -519,873.21 |
| 资产减值损失(新) | -747,170.34 | -21,271,425.23 | -566,920.72 | -433,450.58 |
| 信用减值损失(新) | 8,116,072.78 | 31,550,963.53 | 23,203,124.67 | 22,966,543.42 |
| 其他收益 | 6,656,517.7 | 30,259,482.91 | 26,146,723.09 | 23,543,318.43 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 85,094,634.44 | 279,116,729.59 | 259,653,098.95 | 192,684,195.73 |
| 加:营业外收入 | 2,467,211.92 | 19,234,119.15 | 5,793,737.11 | 828,232.58 |
| 减:营业外支出 | 1,325,030.62 | 2,671,715.99 | 1,735,174.25 | 1,089,066.33 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 86,236,815.74 | 295,679,132.75 | 263,711,661.81 | 192,423,361.98 |
| 减:所得税费用 | 8,184,704.67 | 36,179,157.28 | 40,067,384.61 | 22,692,879.78 |
| 六、净利润 | 78,052,111.07 | 259,499,975.47 | 223,644,277.2 | 169,730,482.2 |
| 持续经营净利润 | 78,052,111.07 | 259,499,975.47 | 223,644,277.2 | 169,730,482.2 |
| 归属于母公司股东的净利润 | 79,096,771.2 | 256,551,420.89 | 229,956,759.59 | 174,865,865.26 |
| 少数股东损益 | -1,044,660.13 | 2,948,554.58 | -6,312,482.39 | -5,135,383.06 |
| (一)基本每股收益 | 0.21 | 0.67 | 0.6 | 0.46 |
| (二)稀释每股收益 | 0.21 | 0.67 | 0.6 | 0.46 |
| 八、其他综合收益 | 20,524.12 | -4,744,187.07 | -1,154,010.01 | -1,336,759.94 |
| 归属于母公司股东的其他综合收益 | 22,343.47 | -4,006,004.46 | -206,236.69 | -191,585.57 |
| 九、综合收益总额 | 78,072,635.19 | 254,755,788.4 | 222,490,267.19 | 168,393,722.26 |
| 归属于母公司股东的综合收益总额 | 79,119,114.67 | 252,545,416.43 | 229,750,522.9 | 174,674,279.69 |
| 归属于少数股东的综合收益总额 | -1,046,479.48 | 2,210,371.97 | -7,260,255.71 | -6,280,557.43 |
| 公告日期 | 2024-04-24 | 2024-04-19 | 2023-10-26 | 2023-08-19 |
| 审计意见(境内) | | 标准无保留意见 | | |